Galcanezumab for the preventive treatment of episodic and chronic migraine in real life: A prospective multicenter study in Colombia and Mexico, including effects on anxiety and depression—on behalf of ASOLAC

Background Galcanezumab is a therapeutic option for individuals with high-frequency episodic and chronic migraine. To date, there is no information regarding treatment results for Colombia and Mexico. The aim of this study was to determine the effectiveness and tolerability of galcanezumab in real-life patients from Colombia and Mexico. Materials and methods This was a prospective, independent, multicenter, real-life study. Ninety-eight patients ≥18 years of age with a diagnosis of episodic and chronic migraine, who received galcanezumab 240 mg as a loading dose followed by galcanezumab 120 mg monthly following the available guidelines, were included. At baseline, 3 months, and 6 months, comparative analyses of migraine days/month, the headache impact test-6 (HIT-6), generalized anxiety disorder-7 (GAD-7), patient health questionnaire-9 (PHQ-9) scales, analgesic days/month, global self-perception, and incidence of collateral effects were performed. Results Ninety-eight patients were included [mean age, 43.6 (standard deviation (SD) = 12.91); age range, 18–82 years; women, 85.7%]. At baseline, 72.4% and 27.6% of patients had chronic migraine and episodic migraine, respectively. In the episodic migraine group, there was a decrease in migraine days from baseline [6.3 (interquartile range (IQR) = 3.5–9] to 6 months [3.6 (IQR = 1.7–5)] of follow-up ( p = 0.01 baseline vs 6 months). Patients with chronic migraine changed from [24.2 (IQR = 22.9–24.9)] at baseline to [12.4 (IQR = 10.9–13.2)] at month 3 and to [10 (IQR = 8.7–11.6)] at the end of follow-up ( p < 0.01). HIT-6, GAD-7, and PHQ-9 scores were significantly lower at months 3 and 6 than at baseline. De novo constipation occurred in 8% of participants. Conclusion This study offers evidence of the effectiveness of galcanezumab in real life, including an impact on psychiatric variables.